Key facts: Sanofi to acquire Dynavax for $2.2B; FDA issues letter on Tolebrutinib
I'm PortAI, I can summarize articles.
Sanofi will acquire Dynavax Technologies for $2.2 billion, paying $15.50 per share, a 39% premium. The deal, enhancing its vaccine portfolio, is set to close in Q1 2026.123Sanofi received a Complete Response Letter from the FDA regarding its New Drug Application for Tolebrutinib, intended for non-relapsing secondary progressive multiple sclerosis treatment.4Sanofi announced that a recent deal is expected to have no impact on its guidance for 2025.5
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments